AU2995497A - Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof - Google Patents

Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof

Info

Publication number
AU2995497A
AU2995497A AU29954/97A AU2995497A AU2995497A AU 2995497 A AU2995497 A AU 2995497A AU 29954/97 A AU29954/97 A AU 29954/97A AU 2995497 A AU2995497 A AU 2995497A AU 2995497 A AU2995497 A AU 2995497A
Authority
AU
Australia
Prior art keywords
hypolipidaemic
antidiabetic
preparation
pharmaceutical compositions
antihypertensive properties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU29954/97A
Inventor
Sekar Reddy Alla
Ranjan Chakrabarti
Braj Bhushan Lohray
Vidya Bhushan Lohray
Rao Bheema Paraselli
Rajagopalan Ramanujam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Research Foundation
Reddy Cheminor Inc
Original Assignee
Dr Reddys Research Foundation
Reddy Cheminor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/687,840 external-priority patent/US5801173A/en
Application filed by Dr Reddys Research Foundation, Reddy Cheminor Inc filed Critical Dr Reddys Research Foundation
Publication of AU2995497A publication Critical patent/AU2995497A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU29954/97A 1996-07-26 1997-05-02 Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof Abandoned AU2995497A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/687,840 US5801173A (en) 1996-05-06 1996-07-26 Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US08687840 1996-07-26
PCT/US1997/007415 WO1997041120A1 (en) 1996-07-26 1997-05-02 Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
AU2995497A true AU2995497A (en) 1997-11-19

Family

ID=24762089

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29954/97A Abandoned AU2995497A (en) 1996-07-26 1997-05-02 Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof

Country Status (5)

Country Link
EP (1) EP0923580A1 (en)
JP (1) JP2000514041A (en)
CN (1) CN1221417A (en)
AU (1) AU2995497A (en)
WO (1) WO1997041120A1 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW577875B (en) * 1997-01-31 2004-03-01 Shionogi & Co Pyrrolidine derivatives with inhibitory activity for phospholipase A2
DE60114996T2 (en) 2000-03-08 2006-08-10 Novo Nordisk A/S LOWERING OF THE SERUM CHOLESTEROL
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6498170B2 (en) 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
KR100551853B1 (en) * 2000-07-19 2006-02-13 에프. 호프만-라 로슈 아게 Pyrimidine derivatives
US7241895B2 (en) 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
MXPA03002580A (en) * 2000-09-26 2003-10-15 Cord Janet I Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation.
EP2243776A1 (en) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
WO2003055482A1 (en) 2001-12-21 2003-07-10 Novo Nordisk A/S Amide derivatives as gk activators
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
MXPA06003474A (en) 2003-09-30 2006-06-05 Novo Nordisk As Melanocortin receptor agonists.
WO2005056036A2 (en) 2003-12-09 2005-06-23 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
PT1723128E (en) 2004-01-06 2013-02-27 Novo Nordisk As Heteroaryl-ureas and their use as glucokinase activators
JP4804346B2 (en) 2004-03-31 2011-11-02 日本曹達株式会社 Cyclic amine compounds and pest control agents
JP2007536344A (en) 2004-05-04 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ New indole derivatives
EP1758575A1 (en) 2004-06-11 2007-03-07 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
CN101060856B (en) 2004-11-22 2011-01-19 诺和诺德公司 Soluble, stable insulin-containing preparations
US8148412B2 (en) 2004-12-03 2012-04-03 Novo Nordisk A/S Heteroaromatic glucokinase activators
EP2386554A1 (en) 2005-07-04 2011-11-16 High Point Pharmaceuticals, LLC Compounds active at the histamine H3 receptor
BRPI0612996A2 (en) 2005-07-14 2010-12-14 Novo Nordisk As urea glucokinase activators
US8106090B2 (en) 2005-07-20 2012-01-31 Eli Lilly And Company 1-amino linked compounds
NZ567127A (en) 2005-10-06 2010-04-30 Nippon Soda Co Bridged cyclic amine compound and pest control agent
DK1951658T3 (en) 2005-11-17 2012-10-15 Lilly Co Eli GLUCAGON RECEPTOR ANTAGONISTS, MANUFACTURING AND THERAPEUTIC APPLICATIONS
US8394842B2 (en) 2006-03-28 2013-03-12 High Point Pharmaceuticals, Llc Benzothiazoles having histamine H3 receptor activity
EP2079732B9 (en) 2006-05-29 2012-03-21 High Point Pharmaceuticals, LLC 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
EP2097388B1 (en) 2006-11-15 2011-09-07 High Point Pharmaceuticals, LLC Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
US8022066B2 (en) 2006-11-15 2011-09-20 High Point Pharmaceuticals, Llc 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
AU2008204530B2 (en) 2007-01-11 2013-08-01 Vtv Therapeutics Llc Urea glucokinase activators
BR112012021231A2 (en) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh method for enhancing plant yield, plant, construct, use of a construct, method for producing a transgenic plant, collectable parts of a plant, products derived from a plant, use of a nucleic acid and method for producing a product
WO2011104378A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
EP2552950A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
EP2670368A4 (en) 2011-02-03 2015-04-15 Pharmedica Ltd New oral dissolving films for insulin administration, for treating diabetes
RU2013145013A (en) 2011-03-28 2015-05-10 Ново Нордиск А/С NEW GLUCAGON ANALOGUES
MY167234A (en) 2011-09-23 2018-08-14 Novo Nordisk As Novel glucagon analogues
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
DK3738434T3 (en) 2011-12-28 2023-12-04 Global Blood Therapeutics Inc Intermediates for obtaining substituted benzaldehyde compounds and methods for using them in increasing tissue oxygenation
AU2014237330A1 (en) 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR102280614B1 (en) 2013-03-15 2021-07-21 글로벌 블러드 테라퓨틱스, 인크. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
BR112015021982B1 (en) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc COMPOUNDS AND THEIR USES FOR HEMOGLOBIN MODULATION
AU2014237361A1 (en) * 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
MY174727A (en) 2013-04-18 2020-05-11 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EA201992707A1 (en) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
SI3102208T2 (en) 2014-02-07 2024-10-30 Global Blood Therapeutics, Inc. Crystalline polymorph of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
AR108435A1 (en) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc PROCESS TO SYNTHETIZE 2-HYDROXI-6 - ((2- (1-ISOPROPIL-1H-PIRAZOL-5-IL) -PIRIDIN-3-IL) METOXI) BENZALDEHYDE
TWI778983B (en) 2016-10-12 2022-10-01 美商全球血液治療公司 Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
JP2020514365A (en) 2017-03-15 2020-05-21 ノヴォ ノルディスク アー／エス Bicyclic compound capable of binding to melanocortin 4 receptor
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
ATE186724T1 (en) * 1987-09-04 1999-12-15 Beecham Group Plc SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES
MX15171A (en) * 1988-03-08 1993-05-01 Pfizer DERIVATIVES OF TIAZOLIDINODIONA HIPOGLICEMICOS
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
FR2680512B1 (en) * 1991-08-20 1995-01-20 Adir NOVEL 2,4-THIAZOLIDINEDIONE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
EP0590793B1 (en) * 1992-08-31 1999-10-13 Sankyo Company Limited Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses
TW245716B (en) * 1992-12-28 1995-04-21 Takeda Pharm Industry Co
AU668818B2 (en) * 1993-04-07 1996-05-16 Taiho Pharmaceutical Co., Ltd. Thiazolidine derivative and pharmaceutical composition containing the same
GB9308487D0 (en) * 1993-04-23 1993-06-09 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
CN1221417A (en) 1999-06-30
EP0923580A1 (en) 1999-06-23
WO1997041120A1 (en) 1997-11-06
JP2000514041A (en) 2000-10-24

Similar Documents

Publication Publication Date Title
AU2930797A (en) Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
AU7640696A (en) Thiazolidinedione derivatives, method for preparing the derivatives and pharmaceutical compositions containing same
HUP0004024A3 (en) Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof
HUP0001539A3 (en) 2-(1-iminoethylamino)ethyl-homocysteine, process for its preparation and pharmaceutical compositions containing the same
HUP0103082A3 (en) Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
AU4048299A (en) Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same
HUP0103404A3 (en) Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
AU3031797A (en) New substituted 2,4-thiazolidinedione derivatives, processes for producing them and pharmaceutical compositions containing them
AU2094397A (en) New arylglycinamide derivatives, processes for preparing them and pharmaceutical compositions containing these compounds
HUP0001555A3 (en) Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation
AU6362796A (en) Substituted 4-phenylaminothiazoles, their process for preparation and the pharmaceutical compositions containing them
AU2001269198A1 (en) Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them
IL160847A0 (en) A hydrate of substituted thiazolidinedione derivative, process for its preparation and pharmaceutical composition comprising the same
ZA973850B (en) Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
IL137494A0 (en) Polypeptide compounds, process for the preparation thereof and pharmaceutical compositions containing the same
AU4070995A (en) Substituted 4-phenylthiazole derivatives, process for their preparation and pharmaceutical compositions containing them
AU2002300593A1 (en) Process for the preparation of thiazolidinedione derivatives
ZA973848B (en) Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
AU6551198A (en) Novel benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them
AU4878997A (en) Novel isoxazol derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the novel compounds
HUP0101234A3 (en) Betha-carboline derivatives, process for their preparation and pharmaceutical compositions thereof
AU8031598A (en) 3-aminoindane derivatives, process for their preparation and pharmaceutical compositions containing them
AU5525199A (en) N-hydroxyacylamino compounds, process for their preparation and pharmaceutical compositions containing them
AU1606997A (en) Novel naphthylpiperazines derived from substituted cycloazanes, method for preparing same, pharmaceutical compositions and use thereof as drugs
AU2823797A (en) Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them